Milia en plaque

Abstract: Milia en plaque is an unusual and rare variant of milia. We now report a Chinese man with numerous milia within an erythematous plaque of the upper and lower eyelids; histology confirmed the diagnosis and showed pericystic inflammation. All but one of the previous 10 reported cases affected the ear or adjacent sites, and to our knowledge, this is the first reported case of milia en plaque affecting the eyelids.

Abstract: Two patients with an unusual cutaneous lesion consisting of milia on an erythematous edematous base are presented; the clinical and histologic features are described. The name "milia en plaque" is proposed for this unusual condition.

Abstract: background. Milia en plaque (MEP) is an unusual entity with a distinctive clinicohistologic appearance. Optimal treatment is unestablished, particularly for MEP located on difficult anatomic areas. objective. To illustrate by a case report the clinical presentation and management of MEP. methods. A 35-year-old woman with numerous tiny cysts within an slightly erythematous base in unilateral periorbital distribution is described. Histology revealed epidermal cysts arranged within the entire dermis. results. Treatment with chemical exfoliating agents, manual extraction, and topical photodynamic therapy resulted in partial improvement. conclusion. Dermatologists should become familiar with this peculiar condition, being significantly rare possibly because of underreporting or misdiagnosis. New treatment procedures must be tried to achieve a successful cosmetic result with minimal risks.

Abstract: shoulder, neck and lace iFig. la.b). A skin biopsy showed features consistent with LE (Fig. 2). Routine laboratory studies showed only a mild pancytopenia. considered to be a result of chemotherapy. Direct immunolluorescence showed linear deposition of IgG, IgA and C5 along the basement membrane zone. Antinuciear antibodies, at a titre of 1:80. and antissDNA. anti-dsDNA and anti-Ro/SS-A antibodies were found: anti-La/SS-B and anti-Sm antibodies were not detected. B-tell and T-cell populations were about threefold lower fhan the normal values. A diagnosis of SCLE was made based on the disseminated psoriasiform lesions, immunological findings and the absence of systemic involvement. The patient was treated with topical betaniethasone valerate. prednisolone, 40 mg daily, and hydroxychloroquine. 200 mg daily. Over the following year, skin lesions gradually cleared completely. No recurrence of SCLE was observed. In May 1996. the patient developed two local recurrences over the operative area, and died from metastatic disease in November 1996.